Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment
Tracking # 20-1204764
Price not reported
There are no ratings for this course
Learn moreCourse overview
This webinar will focus on the harmonization status of commonly used tumor markers-a-fetoprotein (AFP), prostate specific antigen (PSA), carcinoembryonic antigen (CEA), cancer antigen (CA)125, CA15-3 and CA19-9-which are important diagnostic tools in cancer care. For their optimal clinical use, including application of general clinical decision limits, appropriate harmonization status of the measurement procedures is essential. The current status of harmonization will be discussed using data from six international external quality assessment (EQA) scheme providers. The presenters will describe how EQA data can be used to establish the current status of harmonization, including consideration of the importance of commutability in the context of EQA sample distribution. The current status of harmonization for each of the tumor markers will be described, and the clinical and laboratory implications of this discussed. Priority areas for future harmonization/standardization of tumor markers will be identified.
Subject areas
This course counts toward the state boards and subject areas below.
American Board of Clinical Chemistry
Clinical Chemistry Diplomate
Molecular Diagnostics Diplomate
Toxicological Chemistry Diplomate
Florida Board of Clinical Laboratory Personnel
Clinical Laboratory Director
Clinical Laboratory Supervisor
Clinical Laboratory Technician
Clinical Laboratory Technologist
Public Health Director
Public Health Supervisor
Public Health Technologist
Disclosure statements
The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.
The following faculty reported financial relationships:
- Huub van Rossum, EuSpLM, PhD
- Honorarium/Expenses: Huvaros B.V., SelfSafeSure Blood Collections B.V.
- Grant/Research Support: Roche Diagnostics, Health Holland, Stichting Treatmeds
- Board/Committee/Membership/Advisory Board: ISOBM, Huvaros B.V., SelfSafeSure Blood Collections B.V.
- Stocks/Bonds: Huvaros B.V., SelfSafeSure Blood Collections B.V.
- Ownership: Huvaros B.V.
The following faculty reported no financial relationships:
- Ian Young, BSc, MD, FRCP, FRCPath